Review Article

Targeting Angiogenesis in Childhood Sarcomas

Table 1

Summary of select recent clinical studies for sarcoma.

Compounds/Agents in Clinical trialsTumor typeIdentifier

A Phase II trial of dasatinibAdvanced sarcomaSARC009
A Phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptorRecurrent or refractory ewing's sarcoma, osteosarcoma, synovial sarcoma, rhabdomyosarcoma, and other sarcomasSARC011
A randomized, double-blinded, placebo-controlled, multiinstitutional, phase II.5 study of AZD0530, a selective Src kinase inhibitorRecurrent osteosarcoma localized to the lungSARC012
IMC-A12 and doxorubicin hydrochloridePatients with unresectable, locally advanced, or metastatic soft tissue sarcomaNCT00720174
IMC-A12Young patients with relapsed or refractory ewing sarcoma/peripheral primitive neuroectodermal tumor or other solid tumorNCT00609141
R1507Patients with recurrent or refractory sarcomaNCT00642941
CP751871 figitumumab combined with pegvisomantAdvanced solid tumorsNCT00976508
Bevacizumab and AZD2171Patients with metastatic or unresectable solid tumor, lymphoma, intracranial glioblastoma, gliosarcoma, or anaplastic astrocytomaNCT00458731
Cediranib (tentative trade name recentin), also known as AZD2171Young patients with refractory or recurrent solid tumors or acute myeloid leukemiaNCT00354848
Temozolomide, cixutumumab, and combination chemotherapyTreating patients with metastatic rhabdomyosarcomaNCT01055314
Cixutumumab IMC A12Treating patients with relapsed or refractory solid tumorsNCT00831844
Cixutumumab and temsirolimusTreating young patients with solid tumors that have recurred or not responded to treatmentNCT00880282
A study of SCH 717454 in combination with different treatment regimensPediatric subjects with advanced solid tumors (Study P05883)NCT00960063
SCH 717454 in combination with different treatment regimensAdvanced solid tumors (P04722)NCT00954512
Temsirolimus and valproic acidTreating young patients with relapsed neuroblastoma, bone sarcoma, or soft tissue sarcomaNCT01204450
Temsirolimus, irinotecan hydrochloride, and temozolomideTreating young patients with relapsed or refractory solid tumorsNCT01141244
PCI-24781 in combination with doxorubicinTreat sarcomaNCT01027910
Angiogenesis inhibitor SU5416Treating patients with soft tissue sarcomaNCT00023738
Sorafenib and bevacizumabTreating patients with refractory, metastatic, or unresectable solid tumorsNCT00098592
SunitinibTreating patients with metastatic, locally advanced, or locally recurrent sarcomasNCT00474994
Radiation therapy with or without SU5416 (TK inhibitor antiangiogenesis compound)Treating patients with soft tissue sarcomaNCT00023725
Phase II study of doxorubicin and bevacizumab (anti-VEFG monoclonal antibody, NSC 704865)Patients with advanced or metastatic soft-tissue sarcomaNCT00052390
Phase I/II study of gemcitabine, docetaxel, and bevacizumabPatients with soft tissue sarcomaNCT00276055
Phase II study of neoadjuvant bevacizumab and radiation therapy Resectable soft tissue sarcomasNCT00356031

āˆ— Source: http://www.clinicaltrials.gov/.